{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Mask&page=2",
    "query": {
      "intervention": "Active Mask",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Mask&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T03:05:00.309Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04357951",
      "title": "D-cycloserine Augmented Treatment for Youth With Tic Disorders",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Tourette Syndrome"
      ],
      "interventions": [
        {
          "name": "d-cycloserine",
          "type": "DRUG"
        },
        {
          "name": "Placebo pill",
          "type": "DRUG"
        },
        {
          "name": "Behavior Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-04-15",
      "completion_date": "2024-09",
      "has_results": false,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-09-07T03:05:00.309Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04357951"
    },
    {
      "nct_id": "NCT02946125",
      "title": "Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mydriasis"
      ],
      "interventions": [
        {
          "name": "MDD-administered EYN-1601",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Phenylephrine 2.5% Eyedrop",
          "type": "DRUG"
        },
        {
          "name": "Phenylephrine 10% Eyedrop",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Eyenovia Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2016-10",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2022-07-27",
      "last_synced_at": "2026-09-07T03:05:00.309Z",
      "location_count": 1,
      "location_summary": "Artesia, California",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02946125"
    },
    {
      "nct_id": "NCT00784719",
      "title": "A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Syndromes"
      ],
      "interventions": [
        {
          "name": "CP-690,550",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "CP-690,550 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 327,
      "start_date": "2008-11",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-04-09",
      "last_synced_at": "2026-09-07T03:05:00.309Z",
      "location_count": 27,
      "location_summary": "Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00784719"
    },
    {
      "nct_id": "NCT01721330",
      "title": "A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "ADHD",
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 3,
      "start_date": "2012-11",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2016-05-27",
      "last_synced_at": "2026-09-07T03:05:00.309Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01721330"
    },
    {
      "nct_id": "NCT01307644",
      "title": "Web-Based Weight Loss & Weight Maintenance Intervention for Older Rural Women, Also Known as Women Weigh-in for Wellness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "Experimental: Web-based only (WO) weight intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Experimental: WO plus peer-led discussion board (WD)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Experimental: WO & professional email counseling (WE)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "69 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 69 Years · Female only"
      },
      "enrollment_count": 301,
      "start_date": "2011-05-01",
      "completion_date": "2016-08-01",
      "has_results": false,
      "last_update_posted_date": "2023-09-06",
      "last_synced_at": "2026-09-07T03:05:00.309Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01307644"
    },
    {
      "nct_id": "NCT02302079",
      "title": "A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "ASP8232",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sham intravitreal (IVT) injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Astellas Pharma Europe B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 96,
      "start_date": "2015-01-12",
      "completion_date": "2016-08-12",
      "has_results": false,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-09-07T03:05:00.309Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02302079"
    },
    {
      "nct_id": "NCT03913143",
      "title": "A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Leber Congenital Amaurosis 10",
        "Blindness",
        "Leber Congenital Amaurosis",
        "Vision Disorders",
        "Sensation Disorders",
        "Neurologic Manifestations",
        "Eye Diseases",
        "Eye Diseases, Hereditary",
        "Eye Disorders Congenital",
        "Retinal Disease"
      ],
      "interventions": [
        {
          "name": "sepofarsen",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ProQR Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2019-04-04",
      "completion_date": "2023-03",
      "has_results": false,
      "last_update_posted_date": "2022-03-17",
      "last_synced_at": "2026-09-07T03:05:00.309Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03913143"
    },
    {
      "nct_id": "NCT05019521",
      "title": "A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "Danicopan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 365,
      "start_date": "2021-08-23",
      "completion_date": "2025-01-21",
      "has_results": true,
      "last_update_posted_date": "2025-09-05",
      "last_synced_at": "2026-09-07T03:05:00.309Z",
      "location_count": 49,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Encino, California + 45 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05019521"
    },
    {
      "nct_id": "NCT06274749",
      "title": "Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Urolithin A",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "55 Years to 100 Years"
      },
      "enrollment_count": 180,
      "start_date": "2026-09-09",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-07T03:05:00.309Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06274749"
    },
    {
      "nct_id": "NCT00353964",
      "title": "Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Inflammation"
      ],
      "interventions": [
        {
          "name": "rEV131",
          "type": "DRUG"
        },
        {
          "name": "Prenisolone sodium phosphate 1.0%",
          "type": "DRUG"
        },
        {
          "name": "rEV131 vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Evolutec Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-07-28",
      "last_synced_at": "2026-09-07T03:05:00.309Z",
      "location_count": 1,
      "location_summary": "North Andover, Massachusetts",
      "locations": [
        {
          "city": "North Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00353964"
    }
  ]
}